GB2371802A - G-protein coupled receptors - Google Patents

Abstract

An isolated receptor polypeptide having an immunomodulatory or neuromodulatory activity or endocrine function comprising <SL> <LI>(i) the amino acid sequence of SEQ ID NO:2 or <LI>(ii) a variant thereof which shows immunomodulatory or neuromodulatory activity or endocrine function or <LI>(iii) a fragment of (i) or (ii) which shows immunomodulatory or neuromodulatory activity or endocrine function. </SL> The polypeptide, HIPHUM 0000123, is a screening target for agents that may be useful in the treatment and/or prophylaxis of cancer, osteoarthritis, CNS disorders, obesity, NIDM, digestive disorders or diseases related to hypothalamus function.

Description

NEW POLYPEPTIDE

Field of the Invention

The present invention relates to receptor polypeptides having an 5 immunomodulatory or neuromodulatory activity or endocrine function.

Background of the Invention

G-protein coupled receptors (GPCRs) are a super-family of membrane receptors that mediate a wide variety of biological functions. Upon binding of lo extracellular ligands, GPCRs interact with a specific subset of heterotrimeric G proteins that can, in their activated forms, inhibit or activate various effecter enzymes and/or ion channels. All GPCRs are predicted to share a common molecular architecture consisting of seven transmembrane helices linked by alternating intracellular and extracellular loops. The extracellular receptor surface has been 15 shown to be involved in ligand binding whereas the intracellular portions are involved in G protein recognition and activation.

Summary of the Invention

A novel receptor, referred to herein as HIPHUM 0000123, is now provided.

20 HIPHUM 0000123 is shown to be primarily expressed in ovary, urinary bladder, salivary and parotid glands, hypothalamus, cerebral cortex, lung, spleen, thymes, GI tract, uterus, endometrium and heart (Figure 1). The receptor is also expressed in monocytes and endothelial cells (Figure 2) which may account for low level expression in most tissues studied. The receptor is down-regulated in OA cartilage 25 versus normal cartilage and is upregulated in HIV and HBV-infected cells.

HIPHUM 00000123 was expressed in RA synovium and was up-regulated in colon and lung tumors vs. normal tissue (Figure 2). The novel receptor is a screening target for the identification and development of novel pharmaceutical agents, including modulators of receptors having an immunomodulatory or neuromodulatory activity so or endocrine function. These agents may be used in the treatment and/or prophylaxis of disorders such as cancer including lung, colon and breast cancers; disorders of glandular secretion, dry mouth, dry eye; osteoarthritis; all diseases related to

angiogenesis including diabetic retinopathy, tumor metastasis, rheumatoid arthritis, osteoarthritis, hemangiomas, psoriasis, peripheral vascular disease, ischemic heart disease, arteriosclerosis, neovaseular glaucoma and endometriosis; CNS disorders including cognitive dysfunction, seizure disorders, migraine, Alzheimer's disease, 5 attention deficit disorder, mood disorders, neuropathie pain, schizophrenia, depression, psychosis, memory deficit; obesity and non-insulin-dependent diabetes; all diseases of immune, autoimmune, imrnunodef cieney or inflammatory origin such as: asthma, chronic obstructive pulmonary disease (COPD), bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e.g. tendonitis, 0 bursitis, etc.), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, irritable bowel syndrome, gastritis, colitis, AIDS, viral infections, acne vulgaris, septic shock, anaphylaxis, inflammatory pain; female reproductive disorders such as infertility, polyeystie ovary syndrome, endometriosis, dysmenorrhea, pelvic inflammatory disease, fibroids; GI motility (e.g. diarrhoea, constipation) and digestive disorders, diverticular disease; or diseases related to disruption of hypothalamic function such as neuroendocrine disorders and disrupted metastatic control.

Accordingly, the present invention provides an isolated receptor polypeptide having an immunomodulatory or neuromodulatory activity or endocrine function to comprising: (i) the amino acid sequence of SEQ ID NO: 2; (ii) a variant thereof which shows immunomodulatory or neuromodulatory activity or endocrine function; or (iii) a fragment of (i) or (ii) which shows immunomodulatory or 25 neuromodulatory activity or endocrine function.

According to another aspect of the invention there is provided a polynueleotide encoding a polypeptide of the invention which polynucleotide includes a sequence comprising: (a) the nucleic acid sequence of SEQ ID NO: 1 and/or a sequence 30 complementary thereto; (b) a sequence which hybridises under stringent conditions to a sequence as defined in (a);

(c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

5 The invention also provides: - an expression vector which comprises a polynucleotide of the invention and which is capable of expressing a polypeptide of the invention; - a host cell comprising an expression vector of the invention; - a method of producing a polypeptide of the invention which method lo comprises maintaining a host cell of the invention under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide; - an antibody specific for a polypeptide of the invention; - a method for identification of a substance that modulates an immunomodulatory or neuromodulatory activity or endocrine function of the 5 receptor and/or receptor expression, which method comprises contacting a polypeptide, polynucleotide, expression vector or host cell of the invention with a test substance and determining the effect of the test substance on the activity and/or expression of the said polypeptide or the polypeptide encoded by the said polynucleotide, thereby to determine whether the test substance 20 modulates an immunomodulatory or neuromodulatory activity or endocrine function of the receptor and/or receptor expression; - a compound which or modulates an immunomodulatory or neuromodulatory activity or endocrine function of the receptor and which is identifiable by the method referred to above; 25 - a method of treating a subject having a disorder that is responsive to stimulation or modulation of a receptor having an immunomodulatory or neuromodulatory activity or endocrine function, which method comprises administering to said subject an effective amount of a substance of the invention; and 30 - use of a substance that stimulates or modulates an immunomodulatory or neuromodulatory activity or endocrine function of the receptor in the manufacture of a medicament for the treatment or prophylaxis of a disorder

that is responsive to stimulation or modulation of a receptor having an immunomodulatory or neuromodulatory activity or endocrine function Preferably the disorder is selected from cancer including lung, colon and breast cancers; disorders of glandular secretion, dry mouth, dry eye; osteoarthritis; all 5 diseases related to angiogenesis including diabetic retinopathy, tumor metastasis, rheumatoid arthritis, osteoarthritis, hemangiomas, psoriasis, peripheral vascular disease, ischemic heart disease, arteriosclerosis, neovascular glaucoma and endometriosis; CNS disorders including cognitive dysfunction, seizure disorders, migraine, Alzheimer's disease, attention deficit disorder, mood disorders, neuropathic lo pain, schizophrenia, depression, psychosis, memory deficit, obesity and non-insulin-

dependent diabetes; all disease of immune, autoimmune, immunodef ciency or inflammatory origin such as: asthma, chronic obstructive pulmonary disease (COPD), bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e.g. tendonitis, bursitis, etc.), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, irritable bowel syndrome, gastritis, colitis, AIDS, viral infections, acne vulgaris, septic shock, anaphylaxis, inflammatory pain; female reproductive disorders such as infertility, polycystic ovary syndrome, endometriosis, dysmenorrhea, pelvic inflammatory disease, fibroids; GI motility (e.g. diarrhoea, constipation) and digestive disorders, diverticular disease; or 20 diseases related to disruption of hypothalamic function such as neuroendocrine disorders and disrupted metastatic control.

Brief Description of the Figures

Figure I shows the relative expression levels of HIPHUM 0000123 in a :5 variety of human tissues.

Figure 2 shows the expression of HIPHUM 0000123 in a variety of normal and stimulated cell and tissue types.

Brief Description of the Sequences

30 SEQ ID NO: 1 shows the nucleotide and amino acid sequences of human protein HIPHUM 0000123.

SEQ ID NO: 2 is the amino acid sequence alone of HIPHUM 0000123.

Detailed Description of the Invention

Throughout the present specification and the accompanying claims the words

"comprise" and "include" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. That is, these words are s intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

The present invention relates to a human receptor polypeptide, having an immunomodulatory or neuromodulatory activity or an endocrine function, referred to herein as HIPHUM 0000123, and variants thereof. Sequence information for lo HIPHUM 0000123 is provided in SEQ ID NO: 1 (nucleotide and amino acid) and in SEQ ID NO: 2. A polypeptide of the invention thus consists essentially of the amino acid sequence of SEQ ID NO: 2 or of a variant of that sequence, or of a fragment of either thereof.

Polypeptides of the invention may be in a substantially isolated form. It will 5 be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 50%, e.g. more than 80%, 90%, 95% or 99%, by So weight of the polypeptide in the preparation is a polypeptide of the invention.

Routine methods, can be employed to purify and/or synthesise the proteins according to the invention. Such methods are well understood by persons skilled in the art, and include techniques such as those disclosed in Sambrook et al, Molecular Cloning: a Laboratory Manual, 2nd Edition, CSH Laboratory Press, 1989, the disclosure of

25 which is included herein in its entirety by way of reference.

The term "variant" refers to a polypeptide which has a same essential character or basic biological functionality as HIPHUM 0000123. The essential character of HIPHUM 0000123 can be defined as follows: HIPHUM 0000123 is a receptor polypeptide having an immunomodulatory or neuromodulatory activity or 30 endocrine function. Preferably a variant polypeptide is one which shows an immunomodulatory or neuromodulatory activity or endocrine function. A polypeptide having the same essential character as HIPHUM 0000123 may be

Al identified by monitoring for a function of the receptor polypeptide such as immunomodulatory or neuromodulatory activity or endocrine function. A variant receptor may have a role in immune or endothelial cell function. It may have neuromodulatory or neuroendocrine effects. It may have other roles in the CNS 5 (including the hypothalamus), urinary bladder, and female reproductive tissues and may have effects on angiogenesis. A variant receptor may be identified by looking for ligand binding. A variant of HIPHUM 0000123 may have an amino acid-like ligand. A full length variant polypeptide is preferably one which includes a seven transmembrane region. Preferably, a full length variant polypeptide may couple to lo G-protein to mediate intracellular responses.

In another aspect of the invention, a variant is one which does not show the same activity as HIPHIJM 0000123 but is one which inhibits a basic function of HIPHUM 0000123. For example, a variant polypeptide is one which inhibits the immunomodulatory or neuromodulatory activity or endocrine function of HIPHUM 5 0000123, for example by binding to a HIPHUM 0000123 ligand to prevent activity mediated by ligand binding to HIPHUM 0000123.

Typically, polypeptides with more than about 65% identity preferably at least 80% or at least 90% and particularly preferably at least 95% at least 97% or at least 99% identity, with the amino acid sequences of SEQ ID NO: 2, are considered as 20 variants of the proteins. Such variants may include allelic variants and the deletion, modification or addition of single amino acids or groups of amino acids within the protein sequence, as long as the peptide maintains a basic biological functionality of the HIPHUM 0000123 receptor.

Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 25 or 30 substitutions. The modified polypeptide generally retains an immunomodulatory or neuromodulatory activity or an endocrine function of HIPHUM 00000123. Conservative substitutions may be made, for example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for 30 each other.

ALIPHATIC Non-polar G A r Polar-uncharged C S T M l Polar Kim AROMATIC H F W Y

Shorter polypeptide sequences are within the scope of the invention. For example, a peptide of at least 20 amino acids or up to 50, 60, 70, 80, 1 DO, 150 or 200 amino acids in length is considered to fall within the scope of the invention as long as 5 it demonstrates a basic biological functionality of HIPHUM 0000123. In particular, but not exclusively, this aspect of the invention encompasses the situation when the protein is a fragment of the complete protein sequence and may represent a ligand binding region (N-terminal extracellular domain) or an effecter binding region (C terminal intracellular domain). Such fragments can be used to construct chimeric 10 receptors preferably with another 7-transmembrane receptor, more preferably with another member of the family of receptor polypeptides having an immunomodulatory or neuromodulatory activity or endocrine function.

Such fragments of HIPHUM 0000123 or a variant thereof can also be used to raise anti-HIPHUM 0000123 antibodies. In this embodiment the fragment may comprise an epitope of the HIPHUM 0000123 polypeptide and may otherwise not demonstrate the ligand binding or other properties of HIPHUM 0000123.

Polypeptides of the invention may be chemically modified, e.g. post-

translationally modified. For example, they may be glycosylated or comprise modified amino acid residues. They may also be modified by the addition of histidine 20 residues to assist their purification or by the addition of a signal sequence to promote insertion into the cell membrane. Such modified polypeptides fall within the scope

of the term "polypeptide" of the invention.

The invention also includes nucleotide sequences that encode for HIPHUM 0000123 or variant thereof as well as nucleotide sequences which are complementary thereto. The nucleotide sequence may be RNA or DNA including genomic DNA, 5 synthetic DNA or cDNA. Preferably the nucleotide sequence is a DNA sequence and most preferably, a cDNA sequence. Nucleotide sequence information is provided in SEQ ID NO: 1. Such nucleotides can be isolated from human cells or synthesised according to methods well known in the art, as described by way of example in Sambrook et al, 1989.

lo Typically a polynucleotide of the invention comprises a contiguous sequence of nucleotides which is capable of hybridizing under selective conditions to the coding sequence or the complement of the coding sequence of SEQ ID NO: 1.

A polynucleotide of the invention can hybridize to the coding sequence or the complement of the coding sequence of SEQ ID NO: 1 at a level significantly above s background. Background hybridization may occur, for example, because of other

cDNAs present in a cDNA library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence or complement of the coding sequence of SEQ ID NO: 1 is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding 20 sequence of SEQ ID NO: 1. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with 32p, Selective hybridization may typically be achieved using conditions of medium to high stringency. However, such hybridization may be carried out under any suitable conditions known in the art (see Sambrook et al, 1989. For example, if high stringency is required suitable conditions 25 include from 0.1 to 0. 2 x SSC at 60 C up to 65 C. If lower stringency is required suitable conditions include 2 x SSC at 60 C.

The coding sequence of SEQ ID NO: 1 may be modified by nucleotide substitutions, for example from 1, 2 or 3 to 10, 25, 50 or 100 substitutions. The polyoucleotide of SEQ ID NO: 1 may alternatively or additionally be modified by 30 one or more insertions and/or deletions and/or by an extension at either or both ends.

A polynucleotide may include one or more introns, for example may comprise genomic DNA. Additional sequences such as signal sequences which may assist in

: insertion of the polypeptide in a cell membrane may also be included. The modified polynucleotide generally encodes a polypeptide which has a HIPHUM 0000123 receptor activity. Alternatively, a polynucleotide encodes a ligand-binding portion of a polypeptide or a polypeptide which inhibits an activity of HIPHUM 0000123.

5 Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the Table above.

A nucleotide sequence which is capable of selectively hybridizing to the complement of the DNA coding sequence of SEQ ID NO: 1 will generally have at lo least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the coding sequence of SEQ ID NO: 1 over a region of at least 20, preferably at least 30, for instance at least 40, at least 60, more preferably at least 100 contiguous nucleotides or most preferably over the full length of SEQ ID NO: 1.

5 For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul (1993) J. Mol. Evol.

20 36:290-300; Altschul et al (1990) J. Mol. Biol. 215:403-10.

Software for performing BLAST analyses is publicly available through the National Centre for Biotechnology Information (ht p://www.ncbi.nlm.nih. gov/).

This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy 25 some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, 1990). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be 30 increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls offby the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or

more negative-scoring residue alignments; or the end of either sequence is reached.

The BLAST algorithm parameters W. T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (by) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. 5 Sci. USA 89: 10915-10919) aligurnents (B) of SO, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm 10 is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less 5 than about 0.01, and most preferably less than about 0.001.

Any combination of the above mentioned degrees of sequence identity and minimum sizes may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher sequence identity over longer lengths) being preferred. Thus, for example a polynucleotide which has at least 90% sequence 20 identity over 25, preferably over 30 nucleotides forms one aspect of the invention, as does a polynucleotide which has at least 95% sequence identity over 40 nucleotides.

The nucleotides according to the invention have utility in production of the proteins according to the invention, which may take place in vitro, in vivo or ex viva.

The nucleotides may be involved in recombinant protein synthesis or indeed as 2s therapeutic agents in their own right, utilised in gene therapy techniques. Nucleotides complementary to those encoding HIPHUM 0000123, or antisense sequences, may also be used in gene therapy.

Polynucleotides of the invention may be used as a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a 30 revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.

Such primers, probes and other fragments will preferably be at least 10,

preferably at least 15 or at least 20, for example at least 25, at least 30 or at least 40 nucleotides in length. They will typically be up to 40, 50, 60, 70, 100 or 150 nucleotides in length. Probes and fragments can be longer than 150 nucleotides in length, for example up to 200, 300, 400, 500, 600, 700 nucleotides in length, or even s up to a few nucleotides, such as five or ten nucleotides, short of the coding sequence of SEQ ID NO: 1.

The present invention also includes expression vectors that comprise nucleotide sequences encoding the proteins or variants thereof of the invention. Such expression vectors are routinely constructed in the art of molecular biology and may 0 for example involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression. Other suitable vectors would be apparent to persons skilled in the art. By way of further example in this regard we refer to Sambrook et 15 al. 1989.

Polyoucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be 20 used as test compounds in the assays of the invention or may be useful in a method of treatment of the human or animal body by therapy.

Preferably, a polynucleotide of the invention or for use in the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression 25 vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.

A regulatory sequence, such as a promoter, "operably linked" to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.

30 The vectors may be for example, plasmid, virus or phage vectors provided with a origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain

: : one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector. Vectors may be used in vitro, for example for the production of DNA or RNA or used to transfect or transform a host cell, for example, a mammalian host cell. The vectors may also be s adapted to be used in vivo, for example in a method of gene therapy.

Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast promoters include S. cerevisiae GAL4 and ADH promoters, S. pombe nmtl and adh promoter. Mammalian promoters include the metallothionein promoter which can be lo induced in response to heavy metals such as cadmium. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. All these promoters are readily available in the art.

Mammalian promoters, such as p-actin promoters, may be used. Tissue-

specif c promoters are especially preferred. Viral promoters may also be used, for 15 example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or HPV promoters, particularly the HPV upstream regulatory region (URR). Viral promoters are readily available in the art.

o The vector may further include sequences flanking the polynucleotide giving rise to polynucleotides which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the polyoucleotides of the invention

into the genome of eukaryotic cells or viruses by homologous recombination. In s particular, a plasmid vector comprising the expression cassette flanked by viral sequences can be used to prepare a viral vector suitable for delivering the polynucleotides of the invention to a mammalian cell. Other examples of suitable viral vectors include herpes simplex viral vectors and retroviruses, including lentiviruses, adenoviruses, adeno-associated viruses and HPV viruses. Gene transfer 30 techniques using these viruses are known to those skilled in the art. Retrovirus vectors for example may be used to stably integrate the polynucleotide giving rise to the polynucleotide into the host genome. Replication-defective adenovirus vectors

i by contrast remain episomal and therefore allow transient expression.

The invention also includes cells that have been modified to express the HIPHUM 0000123 polypeptide or a variant thereof. Such cells include transient, or preferably stable higher eukaryotic cell lines, such as mammalian cells or insect cells, 5 using for example a baculovirus expression system, lower eukaryotic cells, such as yeast or prokaryotic cells such as bacterial cells. Particular examples of cells which may be modified by insertion of vectors encoding for a polypeptide according to the invention include mammalian HEK293T, CHO, HeLa and COS cells. Preferably the cell line selected will be one which is not only stable, but also allows for mature lo glycosylation and cell surface expression of a polypeptide. Expression may be achieved in transformed oocytes. A polypeptide of the invention may be expressed in cells of a transgenic non-human animal, preferably a mouse. A transgenic non-

human animal expressing a polypeptide of the invention is included within the scope of the invention. A polypeptide of the invention may also be expressed in Xenopus 5 Levis oocytes or melanophores, in particular for use in an assay of the invention. According to another aspect, the present invention also relates to

antibodies, specific for a polypeptide of the invention. Such antibodies are for example useful in purification, isolation or screening methods involving immunoprecipitation techniques or, indeed, as therapeutic agents in their own right.

20 Antibodies may be raised against specie c epitopes of the polypeptides according to the invention. Such antibodies may be used to block ligand binding to the receptor. An antibody, or other compound, "specifically binds" to a protein when it binds with preferential or high affinity to the protein for which it is specific but does substantially bind not bind or binds with only low affinity to other proteins. A 2s variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well known in the art (see for example Maddox et al, J. Exp. Med. 1 58,1 2 1 1 - 1 226,1 993). Such immunoassays typically involve the formation of complexes between the specific protein and its antibody and the measurement of complex formation.

30 Antibodies of the invention may be antibodies to human polypeptides or fragments thereof. For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments which bind a polypeptide of the

invention. Such fragments include Fv, F(ab') and F(ab')2 fragments, as well as single chain antibodies. Furthermore, the antibodies and fragment thereof may be chimeric antibodies, CDR-grafted antibodies or humanised antibodies.

Antibodies may be used in a method for detecting polypeptides of the s invention in a biological sample, which method comprises: I providing an antibody of the invention; II incubating a biological sample with said antibody under conditions which allow for the formation of an antibodyantigen complex; and III determining whether antibody-antigen complex comprising said antibody is lo formed.

A sample may be for example a tissue extract, blood, serum and saliva.

Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions, etc. Antibodies may be linked to a revealing label and thus may be suitable for use in 5 methods of in viva HIPHIJM 0000123 imaging.

Antibodies of the invention can be produced by any suitable method. Means for preparing and characterizing antibodies are well known in the art, see for example Harlow and Lane (1988) "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. For example, an antibody may be 20 produced by raising antibody in a host animal against the whole polypeptide or a fragment thereof, for example an antigenic epitope thereof, herein after the immunogent'. A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and 2s isolating immunoglobulins from the animal's serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified.

A method for producing a monoclonal antibody comprises immortalizing cells which produce the desired antibody. Hybridoma cells may be produced by 30 fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) Nature 256, 495-497).

An immortalized cell producing the desired antibody may be selected by a

conventional procedure. The hybridomas may be grown in culture or injected inuaperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by in vitro immunisation of human lymphocytes, followed by transformation of the 5 lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier.

lo The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

An important aspect of the present invention is the use of polypeptides according to the invention in screening methods. The screening methods may be used to identify substances that bind to receptor polypeptides having an 5 immunomodulatory or neuromodulatory activity or an endocrine function and in particular which bind to HIPHUM 0000123 such as a ligand for the receptor.

Screening methods may also be used to identify agonists or antagonists which may modulate an immunomodulatory or neuromodulatory activity or endocrine function of such a receptor, inhibitors or activators of HIPHUM 0000123 activity, and/or 20 agents which up-regulate or down-regulate HIPHUM 0000123 expression.

Any suitable format may be used for the assay. In general terms such screening methods may involve contacting a polypeptide of the invention with a test substance and monitoring for binding of the test substance to the polypeptide or measuring receptor activity. A polypeptide of the invention may be incubated with a :5 test substance. Modulation of an immunomodulatory or neuromodulatory activity or endocrine function of the receptor may be determined. In a preferred aspect, the assay is a cellbased assay. Preferably the assay may be carried out in a single well of a microtitre plate. Assay formats which allow high throughput screening are preferred. 30 Modulator activity can be determined by contacting cells expressing a polypeptide of the invention with a substance under investigation and by monitoring an effect mediated by the polypeptide. The cells expressing the polypeptide may be

:, in vitro or in viva. The polypeptide of the invention may be naturally or recombinantly expressed. Preferably, the assay is carried out in vitro using cells expressing recombinant polypeptide. Preferably, control experiments are carried out on cells which do not express the polypeptide of the invention to establish whether s the observed responses are the result of activation of the polypeptide.

The binding of a test substance to a polypeptide of the invention can be determined directly. For example, a radiolabelled test substance can be incubated with the polypeptide of the invention and binding of the test substance to the polypeptide can be monitored. Typically, the radiolabelled test substance can be lo incubated with cell membranes containing the polypeptide until equilibrium is reached. The membranes can then be separated from a non-bound test substance and dissolved in scintillation fluid to allow the radioactive content to be determined by scintillation counting. Non-specific binding of the test substance may also be determined by repeating the experiment in the presence of a saturating concentration 5 of a non-radioactive ligand.

Assays may be carried out using cells expressing HIPHUM 0000123, and incubating such cells with the test substance optionally in the presence of HIPHUM 0000123 ligand. Alternatively an antibody may be used to complex HIPHUM 0000123 and thus mediate HIPHUM 0000123 activity. Test substances may then be 20 added to assess the effect on such activity. Cells expressing HIPHUM 0000123 constitutively may be provided for use in assays for HIPHUM 0000123 function.

Such constitutively expressed HIPHUM 0000123 may demonskate HIPHUM 0000123 activity in the absence of ligand binding. Additional test substances may be introduced in any assay to look for inhibitors of ligand binding or inhibitors of 25 HIPHUM 0000123-mediated activity.

In preferred aspects, a host cell is provided expressing the polypeptide and containing a G-protein coupled pathway responsive reporter construct. The host cell is treated with a substance under test for a defined time. The expression of the reporter gene, such as SP alkaline phosphatase or luciferase is assayed. The assay 30 enables determination of whether the compound modulates the induction of the G-

protein coupled pathway by HIPHUM 0000123 in target cells.

Assays may also be carried out to identify modulators of receptorshedding.

: A polypeptide of the invention can be cleaved from the cell surface. Shedding the receptor would act to down regulate receptor signalling. Thus, cell-based assays may be used to screen for compounds which promote or inhibit receptor-shedding.

Assays may also be carried out to identify substances which modify s HIPHUM 0000123 receptor expression, for example substances which up- or down regulate expression. Such assays may be carried out for example by usmg antibodies for HIPHUM 0000123 to monitor levels of HIPHUM 0000123 expression. Other assays which can be used to monitor the effect of a test substance on HIPHUM 0000123 expression include using a reporter gene construct driven by the HIPHUM 0 0000123 regulatory sequences as the promoter sequence and monitoring for expression of the reporter polypeptide. Further possible assays could utilise membrane fractions from overexpression of HIPHUM 0000123 polypeptide either in X Levis oocytes or cell lines such as HEK293, CHO, COS7 and HeLa cells and assessment of displacement of a radiolabelled ligand.

5 Additional control experiments may be carried out. Assays may also be carried out using known ligands of other receptor polypeptides having an immunomodulatory or neuromodulatory activity or endocrine function to identify ligands which are specific for polypeptides of the invention. Preferably, the assays of the invention are carried out under conditions which would result in G-protein 20 coupled pathway mediated activity in the absence of the test substance, to identify inhibitors or activators of receptor polypeptides having an immunomodulatory or neuromodulatory activity or endocrine function, or agents which inhibit ligand-

induced receptor polypeptides having an immunomodulatory or neuromodulatory activity or endocrine function. An assay of the invention may be carried out using a 25 known agonist or antagonist of a receptor having immunomodulatory or neuromodulatory activity or endocrine function to provide a comparison with a compound under test.

Typically, receptor activity can be monitored indirectly for example by measuring a G-protein coupled readout. G-protein coupled readout can typically be 30 monitored using an electrophysiological method to determining the activity of G-

protein regulated Ca2+ or K+ channels or by using a fluorescent dye to measure changed in intracellular Ca2+ levels. The receptor could be coupled to Gs, Gq, Gi

andlor Go. Thus cAMP or GTP(S levels or activity, calcium mobilization, inositol triphosphate generation and protein kinase C activation may be monitored.

Following receptor stimulation, cyclic AMP accumulation can be measured for example in forskolin stimulated CHO cells transformed with the HIPHUM 5 0000123 receptor either directly, or indirectly by monitoring the expression of cotransfected reporter gene, the expression of which will be controlled by cyclic AMP response elements.

Xenopus dermal melanophores aggregate or disperse pigment in response to the activation or inhibition of G-protein coupled receptors. This feature can be lo exploited as an assay for receptor activation or inhibition if a specific G-protein coupled receptor is exogenously expressed.

HIPHUM 0000123 receptor is likely to couple to G-protein with consequent hydrolysis of GTP. Accumulation of a labelled GTP stable analogue can be measured utilising membrane fractions from overexpression of HIPHUM 0000123 5 receptor either inX Levis oocytes or cell lines such as HEK293, CHO, COS7, HeLa on exposure to agonist ligand.

G-protein coupled receptors have been shown to activate MAPK signalling pathways. Cell lines overexpressing the receptor of the invention with MAPK reporter genes may be utilised as assays for receptor activation or inhibition. The 20 receptor of the invention may be heterologously expressed in modif ed yeast strains containing multiple reporter genes, such as FUS 1 -HISS and FUS 1 -lacy, each linked to an endogenous MAPK cascade-based signal transduction pathway. This pathway is normally linked to pheromone receptors, but can be coupled to foreign receptors by replacement of the yeast G-protein with yeast/mammalian G protein chimeras.

25 Strains may also contain two further gene deletions, i.e. deletions of SST2 and FART, to potentiate the assay. Ligand activation of the heterologous receptor can be monitored using the reporter genes, for example either as cell growth in the absence of histidine or with a substrate of beta-galactosidase (lack).

Suitable test substances which can be tested in the above assays include 30 combinatorial libraries, deemed chemical entities and compounds, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display (e.g. phage display libraries) and antibody products.

:i ! Typically, organic molecules will be screened, preferably small organic molecules which have a molecular weight of from 50 to 2500 daltons. Candidate products can be biomolecules including, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Candidate s agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

Test substances may be used in an initial screen of, for example, 10 lo substances per reaction, and the substances of these batches which show inhibition or activation tested individually. Test substances may be used at a concentration of from lnM to 1000pM, preferably from lllM to lOO,uM, more preferably from 1,uM to 10,uM. Preferably, the activity of a test substance is compared to the activity shown by a known activator or inhibitor. A test substance which acts as an inhibitor 5 may produce a 50% inhibition of activity of the receptor. Alternatively a test substance which acts as an activator may produce 50% ofthe maximal activity produced using a known activator.

Another aspect of the present invention is the use of polynucleotides encoding the HIPHUM 0000123 polypeptides of the invention to identify mutations 20 in HIPHUM 0000123 genes which may be implicated in human disorders.

Identification of such mutations may be used to assist in diagnosis or susceptibility to such disorders and in assessing the physiology of such disorders. Polynucleotides may also be used in hybridisation studies to monitor for up- or down-regulation of HIPHUM 0000123 expression. Polynucleotides such as SEQ ID NO: 1 or fragments 25 thereof may be used to identify allelic variants, genomic DNA and species variants.

The present invention provides a method for detecting variation in the expressed products encoded by HIPHUM 0000123 genes. This may comprise determining the level of an HIPHUM 0000123 expressed in cells or determining specific alterations in the expressed product. Sequences of interest for diagnostic 30 purposes include, but are not limited to, the conserved portions as identified by sequence similarity and conservation of inkon/exon structure. The diagnosis may be

performed in conjunction with kindred studies to determine whether a mutation of interest co-segregates with disease phenotype in a family.

Diagnostic procedures may be performed on polynucleotides isolated from an individual or alternatively, may be performed in situ directly upon tissue sections 5 (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Appropriate procedures are described in, for example, Nuovo, G. J., 1992, "PCR In Situ Hybridization: Protocols And Applications", Raven Press, NY). Such analysis techniques include, DNA or RNA blotting analyses, single stranded confirmational polymorphism analyses, in Sits lo hybridization assays, and polymerase chain reaction analyses. Such analyses may reveal both quantitative aspects of the expression pattern of a HIPHUM 0000123, and qualitative aspects of HIPHUM 0000123 expression and/or composition.

Alternative diagnostic methods for the detection of HIPHUM 0000123 nucleic acid molecules may involve their amplification, e.g. by PCR (the 5 experimental embodiment set forth in U.S. Patent No.4,683,202), ligase chain reaction (Barany,1991, Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874 1878), transcriptional amplification system (Kwoh et al., 1989, Proc. Natl. Acad. Sci. 15 USA 86:1173-1177), Q-Beta Replicase (Lizard) et al., 1988, Bio/Technology 20 6:1197) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art.

These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

Particularly suitable diagnostic methods are chip-based DNA technologies 25 such as those described by Hacia et al., 1996, Nature Genetics 14:441447 and Shoemaker et al., 1996, Nature Genetics 14:450-456. Briefly, these techniques involve quantitative methods for analyzing large numbers of nucleic acid sequence targets rapidly and accurately. By tagging with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density 30 arrays and screen these molecules on the basis of hybridization.

Following detection, the results seen in a given patient may be compared with a statistically significant reference group of normal patients and patients that have

HIPHUM 0000123 related pathologies. In this way, it is possible to correlate the amount or kind of HIPHUM 0000123 encoded product detected with various clinical states or predisposition to clinical states.

Another aspect of the present invention is the use of the substances that have 5 been identified by screening techniques referred to above in the treatment of disease states, which are responsive to regulation of an immunomodulatory or neuromodulatory activity or an endocrine function of the receptor. The treatment may be therapeutic or prophylactic. The condition of a patient suffering from such a disease state can thus be improved.

o In particular, such substances may be used in the treatment of cancer including lung, colon and breast cancers; disorders of glandular secretion, dry mouth, dry eye; osteoarthritis; all diseases related to angiogenesis including diabetic retinopathy, tumor metastasis, rheumatoid arthritis, osteoarthritis, hemangiomas, psoriasis, peripheral vascular disease, ischemic heart disease, arteriosclerosis, neovascular glaucoma and endometriosis; CNS disorders including cognitive dysfunction, seizure disorders, migraine, Alzheimer's disease, attention deficit disorder, mood disorders, neuropathic pain, schizophrenia, depression, psychosis, memory deficit; obesity and non-insulin-dependent diabetes; all diseases of immune, autoimmune, immunodef ciency or inflammatory origin such as: asthma, chronic 20 obstructive pulmonary disease (COPD), bronchitis, rhinitis, allergy, rheumatoid: arthritis, dermatitis, general inflammation (e.g. tendonitis, bursitis, etc.), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, irritable bowel syndrome, gastritis, colitis, AIDS, viral infections, acne vulgaris, septic shock, anaphylaxis, inflammatory pain; female reproductive disorders 2s such as infertility, polycystic ovary syndrome, endometriosis, dysmenorrhea, pelvic inflammatory disease, fibroids, GI motility (e.g. diarrhoea, constipation) and digestive disorders, diverticular disease; or diseases related to disruption of hypothalamic function such as neuroendocrine disorders and disrupted metastatic control. so Substances identified according to the screening methods outlined above may be formulated with standard pharmaceutically acceptable carriers and/or excipients as is routine in the pharmaceutical art. For example, a suitable substance may be

dissolved in physiological saline or water for injections. The exact nature of a formulation ill depend upon several factors including the particular substance to be administered and the desired route of administration. Suitable types of formulation are fully described in Remington's Pharmaceutical Sciences, Mack Publishing 5 Company, Eastern Pennsylvania, 17 Ed. 1985, the disclosure of which is included

herein of its entirety by way of reference.

The substances may be administered by enteral or parenteral routes such as via oral, buccal, anal, pulmonary, intravenous, inka-arterial, intramuscular, intraperitoneal, topical or other appropriate administration routes.

lo A therapeutically effective amount of a modulator is administered to a patient. The dose of a modulator may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage 15 for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific modulator, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

20 Nucleic acid encoding HIPHUM 0000123 or a variant thereof which inhibits HIPHUM 0000123 activity may be administered to the mammal. Nucleic acid, such as RNA or DNA, and preferably, DNA, is provided in the form of a vector, such as the polynucleotides described above, which may be expressed in the cells of the mammal. 25 Nucleic acid encoding the polypeptide may be administered by any available technique. For example, the nucleic acid may be introduced by needle injection, preferably intradermally, subcutaneously or intramuscularly. Alternatively, the nucleic acid may be delivered directly across the skin using a nucleic acid delivery device such as particle-mediated gene delivery. The nucleic acid may be so administered topically to the skin, or to mucosal surfaces for example by intranasal, oral, intravaginal or intrarectal administration.

Uptake of nucleic acid constructs may be enhanced by several known

transfection techniques, for example those including the use of transfection agents.

Examples of these agents includes cationic agents, for example, calcium phosphate and DEAE-Dextran and lipofectants, for example, lipofectam and transfecta n. The dosage of the nucleic acid to be administered can be altered. Typically the nucleic 5 acid is administered in the range of lpg to lmg, preferably to lpg to 10pg nucleic acid for particle mediated gene delivery and 10pg to lmg for other routes.

The following Examples illustrate the invention.

Example 1: Characterisation of the sequence A receptor polypeptide, having an immunomodulatory or neuromodulatory 0 activity or endocrine function, designated as HIPHUM 0000123 has been identified.

The nucleotide and amino acid sequences of the receptor have been determined.

These are set out below in SEQ ID NOs: 1 and 2. HIPHUM 0000123 shares approximately 33% homology with the human extracellular calcium-sensing receptor. Hiphum 0000123 also shares approximately 27% with receptor TR1, a taste 15 receptor. The closest known homolog to HIPHUM 0000123 is a goldfish odorant receptor (Neuron 1999 Ju1;23(3):487-98) which has an amino acid ligand. Suitable primers and probes were designed and used to analyse tissue expression. HIPHUM 0000123 was found to be primarily expressed in ovary, urinary bladder, salivary and parotid glands, hypothalamus, cerebral cortex, lung, spleen, thymus, GI tract, uterus, 20 endometrium and heart (Figure 1). The receptor is also expressed in monocytes and endothelial cells (Figure 2) which may account for low level expression in most tissues studied. The receptor is down-regulated in OA cartilage versus normal cartilage and is upregulated in HIV and HBVinfected cells. HIPHUM 00000123 was expressed in RA synovium and was upregulated in colon and lung tumors 25 compared to normal tissue (Figure 2) .

Example 2: Screening for substances which exhibit protein modulating activity Mammalian cells, such as HEK293, CHO and COS7 cells, overexpressing a polypeptide ofthe invention are generated for screening purposes. 96 and 384 well plate, high throughput screens (HTS) are employed using fluorescence based calcium 30 indicator molecules, including but not limited to dyes such as Fura-2, Fura-Red, Fluo 3 and Fluo 4 (Molecular Probes). Secondary screening involves the same

N technology. Tertiary screens involve the study of modulators in rat, mouse and guinea-pig models of disease relevant to the target.

A brief screening assay protocol is as follows: Mammalian cells stably over-expressing a polypeptide of the invention are s cultured in black wall, clear bottom, tissue culture-coated, 96 or 384 well plates with a volume of 100 1 cell culture medium in each well 3 days before use in a FLIPR (Fluorescence Imaging Plate Reader- Molecular Devices). Cells are incubated with 4pM FLUO-3AM at 30 C in 5%CO2 for 9O mins and then washed once in Tyrodes buffer cont ining 3mM probenec d. Basal fluorescence is determined prior to lo addition of test substances. The polypeptide is activated upon the addition of a known agonist. Activation results in an increase in intracellular calcium which can be measured directly in the FLIPR. For antagonist studies, substances are preincubated with the cells for 4 minutes following dye loading and washing and fluorescence measured for 4 minutes. Agonists are then added and cell fluorescence measured for 5 a further 1 minute.

Assays may also be carried out as follows: Gs-coupled receptors are expressed and assayed in mammalian cells which express the 6xCREluciferase reporter gene such as CHO cells. Gq-coupled and Gi coupled receptors are expressed and assayed in mammalian cells which express the 20 Gal4/Elk-1 chimeric protein and 5xUAS-luciferase reporter gene. Cells are propagated in either in suspension or adherent cultures.

For adherent culture, cells are propagated in T225 flasks in DMEM/F12 containing 5% fetal bovine serum and 1 mM glutamine. Forty-eight hours prior to assay, cells are harvested with 2 ml of 0.05% trypsin, washed with complete medium 25 and plated at a concentration of 4,000 cells/well in complete medium. Sixteen hours prior to the assay, the medium is removed from the cells and replaced with 90 ul/well of serum-free DMEM/F12. At the time of the assay, test substances are added to the wells at a final concentration of 10,uM and the plates are incubated for four hours at 37 C in a cell culture incubator. The medium is aspirated by vacuum followed by 30 the addition of 50,ul of a 1:1 mixture of LucLite_ and dPBS/1 mM CaCl2/1 mM MgCl2. Plates are sealed and subjected to dark adaptation at room temperature for 10

2s minutes before luciferase activity is quantitated on a TopCount_ microplate scintillation counter (Packard) using 3 seconds/well count time.

For suspension cultures, cells are propagated in Excel 301 medium containing 5% FBS and 2 mM glutamine at a minimum of 1x105 cells/ml for one week. Sixteen s hours prior to an assay, cells are removed from suspension by centrifugation and resuspended in serum-free Excel 301 at a concentration of 1x106 cells/ml. At the time of assay, the cells are. resuspended in serum-free DMEM/F12 at a concentration of 50,000 cells/ml. 100,ul/well or 50,ul/well of this suspension is pipetted into black 96-well or 384-well plates, respectively. The 96-well and 384-well plate contained 1 10 ul or 0.5 Ill of agonist compounds in 100% DMSO at a final concentration of 10 M. A Multidrop S20 cell dispenser is used to dispense cells into either 96- or 384-well plates. The reminder of the assay is the same as described for adherent culture above. Xenopus oocyte expression l5 Adult female Xenopus Levis (Blades Biologicals) are anaesthetised using 0.2% tricaine (3-aminobenzoic acid ethyl ester), killed and the ovaries rapidly removed. Oocytes are then de-folliculated by collagenase digestion (Sigma type I, 1.5 mg ml) in divalent cation- free OR2 solution (82.5mM NaCl, 2.5mM KCl, 1.2mM NaH2PO4, 5mM HEPES; pH 7. 5 at 25 C). Single stage V and VI oocytes are 20 transferred to ND96 solution (96mM NaCl, 2mM KCl, lmM MgCl2, SmM HEPES, 2.5mM sodium pyruvate, pH 7.5 at 25 C) which contains 50,ug ml ' gentamycin and stored at 18 C.

The EDG-like receptor (in pcDNA3, Invitrogen) is linearised and transcribed to RNA using T7 (Promega Wizard kit). m'G(5')pp(5')GTP capped cRNA is 25 injected into oocytes (20-50ng per oocyte) and whole-cell currents are recorded using two-microelectrode voltage-clamp (Geneclamp amplifier, Axon instruments Inc.) 3 to 7 days post-RNA injection. Microelectrodes have a resistance of 0.5 to 2MQ when filled with 3M KC1.

Melanophore screens may be carried out as follows: 30 Modified or unmodified receptors are expressed in melanophores using appropriate vector constructs including pJG3.6. The expressed receptors are then

screened for Gs, Gq, Gi or Go activity. When a ligand binds to a Gscoupled receptor, it activates adenylyl cyclase that in turn activates protein kinase A. This results in the initiation of phosphorylation events that cause the melanosomes to disperse. When a Gj-coupled receptor is activated, it inhibits adenylyl cyclase which 5 in turn reverses the pigment dispersion process to result in aggregation. When a Gq-

coupled receptor is activated, it activates phospholipase C, which in turn activates protein kinase C. This results in the initiation of phosphorylation events to cause melanosome dispersion. The expressed receptors can be screened in agonist, antagonist or constitutive modes using bead-based lawn format or 96-well, 384-well lo or 1536-well formats.

Melanophores are grown in conditioned fibroblast medium (CFM) at room temperature. After harvesting the cells with trypsin/EDTA, approximately 6 to 10 million cells are electroporated with relevant receptor- expression vectors at 475 V, 425 pFd, 720 ohms. The transfected cells are then plated into T225 flasks and are incubated for 24 hours. Cells are then harvested and plated into assay plates and incubated for 24 hours. Test substances are added to wells at 10 uM final concentration and 30- 120 minutes later the dispersion or aggregation is measured using an SET Spectra plate reader. For dispersion assays, cells are first treated with 2 nM melatonin in assay buffer (0.7X Ll5/0.1% BSA) for 60 minutes before addition 20 of test compounds. For aggregation assays, CFM is replaced with the assay buffer and cells are incubated for 60 minutes before addition of test compounds.

SEQUENCE LISTING

cilo GLAXO GROUP LIMITED S <120> NEW POLYPEPTIDE

cl30> QG 1029(P80204) <140> 10 <141>

c160> Z c170> PatentIn Ver. 2.1 c210> 1 <211> 2646

<212> DNA

<213> Homo sapiens C220> c221> CDS c222> (1)..(2646) 25 <400> 1

atg tcc ata gaa gag tta tgt let get ttc aaa aaa tac ttg ttt ccc 48 Met Ser Ile Glu Glu Leu Cys Ser Asp Phe Lys Lys Tyr Leu Phe Pro 1 5 10 15

30 aac agc ttt gaa ata lea gtt ttt ctt caa act ctt gcc atg ata cac 96 Asn Ser Phe Glu Ile Ser Val Phe Leu Gln Thr Leu Ala Met Ile His 20 25 30

agc att gag atg ale aac eat lea ace ctc tta cct gga gtc aaa ctg 144 35 Ser Ile Glu Met Ile Asn Asn Ser Thr Leu Leu Pro Gly Val Lys Leu 35 40 45

ggg tat gaa ale tat gac act tgt ace gaa gtc ace gtg gca atg gca 192 Gly Tyr Glu Ile Tyr Asp Thr Cys Thr Glu Val Thr Val Ala Met Ala 40 50 55 60

gcc act ctg agg ttt ctt let aaa ttc aac tgc tcc age gaa act gtg 240 Ala Thr Leu Arg Phe Leu Ser Lys Phe Asn Cys Ser Arg Glu Thr Val 65 70 75 80

gag ttt aag tgt gac tat tcc agc tac atg cca age gtt aag gct gtc 288 Glu Phe Lys Cys Asp Tyr Ser Ser Tyr Met Pro Arg Val Lys Ala Val 85 90 95

SO ata ggt let ggg tac lea gee ata act atg gct gtc tcc agg atg ttg 336 Ile Gly Ser Gly Tyr Ser Glu Ile Thr Met Ala Val Ser Arg Met Leu 100 105 110

eat tta cag ctc atg cca cag gtg ggt tat gaa lea act gca gaa ale 384 55 Asn Leu Gln Leu Met Pro Gln Val Gly Tyr Glu Ser Thr Ala Glu Ile 115 120 125

ctg agt gac aaa att cgc ttt cct lea ttt tta cgg act gtg ccc agt 432 Leu Ser Asp Lys Ile Arg Phe Pro Ser Phe Leu Arg Thr Val Pro Ser 130 135 140

5 gac ttc cat caa att aaa gca atg gct cac ctg att cag aaa let ggt 480 Asp Phe His Gln Ile Lys Ala Met Ala His Leu Ile Gln Lys Ser Gly 145 150 155 160

tgg aac tgg att ggc ale ata acc ace get get gac tat gga cga ttg 528 10 Trp Asn Trp Ile Gly Ile Ile Thr Thr Asp Asp Asp Tyr Gly Arg Leu 165 170 175

gct ctt aac act ttt ata att cag gct gaa gca eat aac gtg tgc ata 576 Ala Leu Asn Thr Phe Ile Ile Gln Ala Glu Ala Asn Asn Val Cys Ile 15 180 185 190

gcc ttc aaa gag gtt ctt cca gcc ttt ctt lea get eat acc att gaa 624 Ala Phe Lys Glu Val Leu Pro Ala Phe Leu Ser Asp Asn Thr Ile Glu 195 200 205

gtc age ale eat cgg ace ctg aag aaa ale att tta gaa gcc cag gtt 672 Val Arg Ile Asn Arg Thr Leu Lys Lys Ile Ile Leu Glu Ala Gln Val 210 215 220

25 eat gtc att gtg gta ttt ctg agg caa ttc cat gtt ttt get ctc ttc 720 Asn Val Ile Val Val Phe Leu Arg Gln Phe His Val Phe Asp Leu Phe 225 230 235 240

eat aaa gcc att gaa atg eat ata eat aag atg tgg att gct agt get 768 30 Asn Lys Ala Ile Glu Met Asn Ile Asn Lys Met Trp Ile Ala Ser Asp 245 250 255

eat tgg lea act gcc acc aag att acc acc att cct eat gtt aaa aag 816 Asn Trp Ser Thr Ala Thr Lys Ile Thr Thr Ile Pro Asn Val Lys Lys 35 260 265 270

att ggc aaa gtt gta ggg ttt gcc ttt age age ggg eat ata tcc let 864 Ile Gly Lys Val Val Gly Phe Ala Phe Arg Arg Gly Asn Ile Ser Ser 275 280 285

ttc cat tcc ttt ctt caa eat ctg cac ttg ctt ccc agt gac agt cac 912 Phe His Ser Phe Leu Gln Asn Leu His Leu Leu Pro Ser Asp Ser His 290 295 300

45 aaa ctc tta cat gaa tat gcc atg cat tta let gcc tgc gca tat gtc 960 Lys Leu Leu His Glu Tyr Ala Met His Leu Ser Ala Cys Ala Tyr Val 305 310 315 320

aag gac act get ttg agt caa tgc ata ttc eat cat let caa agg act 1008 50 Lys Asp Thr Asp Leu Ser Gln Cys Ile Phe Asn His Ser Gln Arg Thr 325 330 335

ttg gcc tac aag gct aac aeg gct ata gaa agg aac ttc gtc atg age 1056 Leu Ala Tyr Lys Ala Asn Lys Ala Ile Glu Arg Asn Phe Val Met Arg 55 340 345 350

eat gac ttc ctc tgg gac tat gct gag cca gga ctc att cat agt att 1104 Asn Asp Phe Leu Trp Asp Tyr Ala Glu Pro Gly Leu Ile His Ser Ile 355 360 365

5 cag ctt gca gtg ttt gcc ctt ggt tat gcc.att cgg get ctg tgt caa 1152 Gln Leu Ala Val Phe Ala Leu Gly Tyr Ala Ile Arg Asp Leu Cys Gln 370 375 380

gct cgt gac tgt cag aac ccc aac gcc ttt caa cca tgg gag tta ctt 1200 IO Ala Arg Asp Cys Gln Asn Pro Asn Ala Phe Gln Pro Trp Glu Leu Leu 385 390 395 400

ggt gtg cta aaa eat gtg ace ttc act get gga tgg aet lea ttt cat 1248 Gly Val Leu Lys Asn Val Thr Phe Thr Asp Gly Trp Asn Ser Phe His 15 405 410 415

ttt get gct cac 999 get tta eat act gga tat get gtt gtg ctc tgg 1296 Phe Asp Ala His Gly Asp Leu Asn Thr Gly Tyr Asp Val Val Leu Trp 420 425 430

aag gag ale eat gga cac atg act gtc act aag atg gca gee tat gac 1344 Lys Glu Ile Asn Gly His Met Thr Val Thr Lys Met Ala Glu Tyr Asp 435 440 445

25 cta cag eat get gtc ttc ale ale cca get cag gaa ace aaa eat gag 1392 Leu Gln Asn Asp Val Phe Ile Ile Pro Asp Gln Glu Thr Lys Asn Glu 450 455 460

ttc agg aet ctt aag tta act cta ttt let gtt cta ace aaa ctg aaa 1440 30 Phe Arg Asn Leu Lys Leu Thr Leu Phe Ser Val Leu Thr Lys Leu Lys 465 470 475 480

cat cag aag age att cca gtg gcc act gtc ace let gtg cca gta ccc 1488 His Gln Lys Arg Ile Pro Val Ala Thr Val Thr Ser Val Pro Val Pro 35 485 490 495

ctg cct tcc ale tgg cac tat age cag act gtc tgt gcc cct agt caa 1536 Leu Pro Ser Ile Trp His Tyr Arg Gln Thr Val Cys Ala Pro Ser Gln 500 505 510

get atg cct cac tgc ctt tta tgc aac aac aaa act cac tgg gcc cct 1584 Asp Met Pro His Cys Leu Leu Cys Asn Asn Lys Thr His Trp Ala Pro 515 520 525

4s gtt agg agc act atg tgc ttt gaa aag gaa gtg gaa tat ctc aac tgg 1632 Val Arg Ser Thr Met Cys Phe Glu Lys Glu Val Glu Tyr Leu Asn Trp 530 535 540

eat gac tcc ttg gcc ale cta ctc ctg att ctc tcc cta ctg gga ale 1680 50 Asn Asp Ser Leu Ala Ile Leu Leu Leu Ile Leu Ser Leu Leu Gly Ile 545 550 555 560

ata ttt gtt ctg gtt gtt ggc ata ata ttt ace age aac ctg aac ace 1728 Ile Phe Val Leu Val Val Gly Ile Ile Phe Thr Arg Asn Leu Asn Thr 55 565 570 575

cct gtt gtg aaa tca tcc ggg gga tta aga gtc tgc tat gtg atc ctt 1776 Pro Val Val Lys Ser Ser Gly Gly Leu Arg Val Cys Tyr Val Ile Leu 580 585 590

5 ctc tgt cat ttc ctc aat ttt gcc agc acg agc ttt ttc att gga gaa 1824 Leu Cys His Phe Leu Asn Phe Ala Ser Thr Ser Phe Phe Ile Gly Glu 595 600 605

cca caa gac ttc aca tgt aaa acc agg cag aca atg ttt gga gtg agc 1872 10 Pro Gln Asp Phe Thr Cys Lys Thr Arg Gln Thr Met Phe Gly Val Ser 610 615 620

ttt act ctt tgc atc tcc tgc att ttg acg aag tct ctg aaa att ttg 1920 Phe Thr Leu Cys Ile Ser Cys Ile Leu Thr Lys Ser Leu Lys Ile Leu 15 625 630 635 640

cta gcc ttc agc ttt gat ccc aaa tta cag aaa ttt ctg aag tgc ctc 1968 Leu Ala Phe Ser Phe Asp Pro Lys Leu Gln Lys Phe Leu Lys Cys Leu 645 650 655

tat aga ccg atc ctt att atc ttc act tgc acg ggc atc cag gtt gtc 2016 Tyr Arg Pro Ile Leu Ile Ile Phe Thr Cys Thr Gly Ile Gln Val Val 660 665 670

25 att tgc aca ctc tgg cta atc ttt gca gca cct act gta gag gtg aat 2064 Ile Cys Thr Leu Trp Leu Ile Phe Ala Ala Pro Thr Val Glu Val Asn 675 680 685

gtc tcc ttg ccc aga gtc atc atc ctg gag tgt gag gag gga tcc ata 2112 30 Val Ser Leu Pro Arg Val Ile Ile Leu Glu Cys Glu Glu Gly Ser Ile 690 695 700

ctt gca ttt ggc acc atg ctg ggc tac att gcc atc ctg gcc ttc att 2160 Leu Ala Phe Gly Thr Met Leu Gly Tyr Ile Ala Ile Leu Ala Phe Ile 35 705 710 715 720

tgc ttc ata ttt gct ttc aaa ggc aaa tat gag aat tac aat gaa gcc 2208 Cys Phe Ile Phe Ala Phe Lys Gly Lys Tyr Glu Asn Tyr Asn Glu Ala 725 730 735

aaa ttc att aca ttt ggc atg ctc att tac ttc ata gct tgg atc aca 2256 Lys Phe Ile Thr Phe Gly Met Leu Ile Tyr Phe Ile Ala Trp Ile Thr 740 745 750

45 ttc atc cct atc tat gct acc aca ttt ggc aaa tat gta cca gct gtg 2304 Phe Ile Pro Ile Tyr Ala Thr Thr Phe Gly Lys Tyr Val Pro Ala Val 755 760 765

gag att att gtc ata tta ata tct aac tat gga atc ctg tat tgc aca 2352 50 Glu Ile Ile Val Ile Leu Ile Ser Asn Tyr Gly Ile Leu Tyr Cys Thr 770 775 780

ttc atc ccc aaa tgc tat gtt att att tgt aag caa gag att aac aca 2400 Phe Ile Pro Lys Cys Tyr Val Ile Ile Cys Lys Gln Glu Ile Asn Thr 55 785 790 795 800

aag let gcc ttt ctc aag atg ale tac agt tat let tcc cat agt gtg 2448 Lys Ser Ala Phe Leu Lys Met Ile Tyr Ser Tyr Ser Ser His Ser Val 805 810 815

S agc agc att gcc ctg agt cct gct lea ctg gac tcc atg agc ggc eat 2496 Ser Ser Ile Ala Leu Ser Pro Ala Ser Leu Asp Ser Met Ser Gly Asn 820 825 830

gtc ace atg acc eat ccc agc let agt ggc aag let gca acc tgg cag 2544 IO Val Thr Met Thr Asn Pro Ser Ser Ser Gly Lys Ser Ala Thr Trp Gln 835 840 845

aaa agc aaa get ctt cag gca caa gca ttt gca cac ata tgc agg gaa 2592 Lys Ser Lys Asp Leu Gln Ala Gln Ala Phe Ala His Ile Cys Arg Glu 15 850 855 860

eat gcc ace agt gta let aaa act ttg cct cga aaa age atg lea agt 2640 Asn Ala Thr Ser Val Ser Lys Thr Leu Pro Arg Lys Arg Met Ser Ser 865 870 875 880

ata tga 2646 Ile 25 <2lo> 2 c211> 881 c212> PRT <213> Homo sapiens 30 c400> 2 Met Ser Ile Glu Glu Leu Cys Ser Asp Phe Lys Lys Tyr Leu Phe Pro 1 5 10 15

Asn Ser Phe Glu Ile Ser Val Phe Leu Gln Thr Leu Ala Met Ile His 35 20 25 30

Ser Ile Glu Met Ile Asn Asn Ser Thr Leu Leu Pro Gly Val Lys Leu 35 40 45

40 Gly Tyr Glu Ile Tyr Asp Thr Cys Thr Glu Val Thr Val Ala Met Ala 50 55 60

Ala Thr Leu Arg Phe Leu Ser Lys Phe Asn Cys Ser Arg Glu Thr Val 65 70 75 80

Glu Phe Lys Cys Asp Tyr Ser Ser Tyr Met Pro Arg Val Lys Ala Val 85 90 95

Ile Gly Ser Gly Tyr Ser Glu Ile Thr Met Ala Val Ser Arg Met Leu 50 100 105 110

Asn Leu Gln Leu Met Pro Gln Val Gly Tyr Glu Ser Thr Ala Glu Ile 115 120 125

SS Leu Ser Asp Lys Ile Arg Phe Pro Ser Phe Leu Arg Thr Val Pro Ser 130 135 140

Asp Phe His Gln Ile Lys Ala Met Ala His Leu Ile Gln Lys Ser Gly 145 150 155 160

Trp Asn Trp Ile Gly Ile Ile Thr Thr Asp Asp Asp Tyr Gly Arg Leu 5 165 170 175

Ala Leu Asn Thr Phe Ile Ile Gln Ala Glu Ala Asn Asn Val Cys Ile 180 185 190

10 Ala Phe Lys Glu Val Leu Pro Ala Phe Leu Ser Asp Asn Thr Ile Glu 195 200 205

Val Arg Ile Asn Arg Thr Leu Lys Lys Ile Ile Leu Glu Ala Gln Val 210 215 220

Asn Val Ile Val Val Phe Leu Arg Gln Phe His Val Phe Asp Leu Phe 225 230 235 240

Asn Lys Ala Ile Glu Met Asn Ile Asn Lys Met Trp Ile Ala Ser Asp 20 245 250 255

Asn Trp Ser Thr Ala Thr Lys Ile Thr Thr Ile Pro Asn Val Lys Lys 260 265 270

25 Ile Gly Lys Val Val Gly Phe Ala Phe Arg Arg Gly Asn Ile Ser Ser 275 280 285

Phe His Ser Phe Leu Gln Asn Leu His Leu Leu Pro Ser Asp Ser His 290 295 300

Lys Leu Leu His Glu Tyr Ala Met His Leu Ser Ala Cys Ala Tyr Val 305 310 315 320

Lys Asp Thr Asp Leu Ser Gln Cys Ile Phe Asn His Ser Gln Arg Thr 35 325 330 335

Leu Ala Tyr Lys Ala Asn Lys Ala Ile Glu Arg Asn Phe Val Met Arg 340 345 350

40 Asn Asp Phe Leu Trp Asp Tyr Ala Glu Pro Gly Leu Ile His Ser Ile 355 360 365

Gln Leu Ala Val Phe Ala Leu Gly Tyr Ala Ile Arg Asp Leu Cys Gln 370 375 380

Ala Arg Asp Cys Gln Asn Pro Asn Ala Phe Gln Pro Trp Glu Leu Leu 385 390 395 400

* Gly Val Leu Lys Asn Val Thr Phe Thr Asp Gly Trp Asn Ser Phe His 50 405 410 415

Phe Asp Ala His Gly Asp Leu Asn Thr Gly Tyr Asp Val Val Leu Trp 420 425 430

55 Lys Glu Ile Asn Gly His Met Thr Val Thr Lys Met Ala Glu Tyr Asp 435 440 445

Leu Gln Asn Asp Val Phe Ile Ile Pro Asp Gln Glu Thr Lys Asn Glu 450 455 460

Phe Arg Asn Leu Lys Leu Thr Leu Phe Ser Val Leu Thr Lys Leu Lys 5 465 470 475 480

His Gln Lys Arg Ile Pro Val Ala Thr Val Thr Ser Val Pro Val Pro 485 490 495

IO Leu Pro Ser Ile Trp His Tyr Arg Gln Thr Val Cys Ala Pro Ser Gln 500 505 510

Asp Met Pro His Cys Leu Leu Cys Asn Asn Lys Thr His Trp Ala Pro 515 520 525

Val Arg Ser Thr Met Cys Phe Glu Lys Glu Val Glu Tyr Leu Asn Trp 530 535 540

Asn Asp Ser Leu Ala Ile Leu Leu Leu Ile Leu Ser Leu Leu Gly Ile 20 545 550 555 560

Ile Phe Val Leu Val Val Gly Ile Ile Phe Thr Arg Asn Leu Asn Thr 565 570 575

25 Pro Val Val Lys Ser Ser Gly Gly Leu Arg Val Cys Tyr Val Ile Leu 580 585 590

Leu Cys His Phe Leu Asn Phe Ala Ser Thr Ser Phe Phe Ile Gly Glu 595 600 605

Pro Gln Asp Phe Thr Cys Lys Thr Arg Gln Thr Met Phe Gly Val Ser 610 615 620

Phe Thr Leu Cys Ile Ser Cys Ile Leu Thr Lys Ser Leu Lys Ile Leu 35 625 630 635 640

Leu Ala Phe Ser Phe Asp Pro Lys Leu Gln Lys Phe Leu Lys Cys Leu 645 650 655

40 Tyr Arg Pro Ile Leu Ile Ile Phe Thr Cys Thr Gly Ile Gln Val Val 660 665 670

Ile Cys Thr Leu Trp Leu Ile Phe Ala Ala Pro Thr Val Glu Val Asn 675 680 685

Val Ser Leu Pro Arg Val Ile Ile Leu Glu Cys Glu Glu Gly Ser Ile 690 695 700

Leu Ala Phe Gly Thr Met Leu Gly Tyr Ile Ala Ile Leu Ala Phe Ile 50 705 710 715 720

Cys Phe Ile Phe Ala Phe Lys Gly Lys Tyr Glu Asn Tyr Asn Glu Ala 725 730 735

55 Lys Phe Ile Thr Phe Gly Met Leu Ile Tyr Phe Ile Ala Trp Ile Thr 740 745 750

i Phe Ile Pro Ile Tyr Ala Thr Thr Phe Gly Lys Tyr Val Pro Ala Val 755 760 765

Glu Ile Ile Val Ile Leu Ile Ser Asn Tyr Gly Ile Leu Tyr Cys Thr 5 770 775 780

Phe Ile Pro Lys Cys Tyr Val Ile Ile Cys Lys Gln Glu Ile Asn Thr 785 790 795 800

10 Lys Ser Ala Phe Leu Lys Met Ile Tyr Ser Tyr Ser Ser His Ser Val 805 810 815

Ser Ser Ile Ala Leu Ser Pro Ala Ser Leu Asp Ser Met Ser Gly Asn 820 825 830

Val Thr Met Thr Asn Pro Ser Ser Ser Gly Lys Ser Ala Thr Trp Gln 835 840 845

Lys Ser Lys Asp Leu Gln Ala Gln Ala Phe Ala His Ile Cys Arg Glu 20 850 855 860

Asn Ala Thr Ser Val Ser Lys Thr Leu Pro Arg Lys Arg Met Ser Ser 865 870 875 880

25 Ile

Claims (16)

1. An isolated receptor polypeptide having an immunomodulatory or neuromodulatory activity or endocrine function comprising: (i) the amino acid sequence of SEQ ID NO: 2 or 5 (ii) a variant thereof which shows imrnunomodulatory or neuromodulatory activity or endocrine function; or (iii) a fragment of (i) or (ii) which shows immunomodulatory or neuromodulatory activity or endocrine function.

2. A polypeptide according to claim l wherein the variant (ii) has at least lo 80% identity to the amino acid sequence of SEQ ID NO: 2.

3. A polynucleotide encoding a polypeptide according to claim 1 or 2.

4. A polynucleotide according to claim 3 which is a cDNA sequence.

5. A polynucleotide encoding a receptor polypeptide having an immunomodulatory or neuromodulatory activity or endocrine function which 5 polynucleotide comprises: (a) the nucleic acid sequence of SEQ ID NO: 1 and/or a sequence complementary thereto; (b) a sequence which hybridises under stringent conditions to a sequence as defined in (a); 20 (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

6. An expression vector comprising a polynucleotide according to any 25 one of claims 3 to 5.

7. A host cell comprising an expression vector according to claim 6.

8. An antibody specific for a polypeptide according to claim 1 or 2.

9. A method for the identification of a substance that modulates an immunomodulatory or neuromodulatory activity or endocrine function of the 30 receptor and/or receptor expression, which method comprises: (i) contacting a test substance and a polypeptide according to claim 1 or 2, a polynucleotide according to any one of claims 3 to 5, an

expression vector according to claim 6 or a host cell according to claim 7, and (ii) determining the effect of the test substance on the activity and/or expression of the said polypeptide or the polypeptide encoded by said 5 polynucleotide, thereby to determine whether the test substance modulates an immunomodulatory or neuromodulatory activity or endocrine function of the receptor and/or receptor expression.

l O. A method according to claim 9 wherein the polypeptide is expressed in a cell.

I o

l 1. A substance which modulates an immunomodulatory or neuromodulatory activity or endocrine function of a receptor and which is identifiable by a method according to claim 9 or 10.

12. A method of treating a subject having a disorder that is responsive to stimulation or modulation of a receptor having an immunomodulatory or 5 neuromodulatory activity or endocrine function, which method comprises administering to said subject an effective amount of a substance according to claim 11.

13. A method according to claim 12 wherein the disorder is selected from cancer; disorders of glandular secretion; osteoarthritis; diseases related to 20 angiogenesis; CNS disorders; obesity and non-insulin-dependent diabetes; diseases of immune, autoimmune, immunodeficiency or inflammatory origin; female reproductive disorders; GI motility and digestive disorders; or diseases related to disruption of hypothalamic function.

14. Use of a substance as defined in claim 11 in the manufacture of a 2s medicament for treatment or prophylaxis of a disorder that is responsive to stimulation or modulation of a receptor having an immunomodulatory or neuromodulatory activity or endocrine function

15. A use according to claim 14 wherein the disorder is selected from cancer; disorders of glandular secretion; osteoarthritis; diseases related to 30 angiogenesis, CNS disorders; obesity and non-insulin-dependent diabetes; diseases of immune, autoimmune, immunodeficiency or inflammatory origin; female reproductive disorders; GI motility and digestive disorders; or diseases related to

disruption of hypothalamic function.

16. A method of producing a polypeptide according to claim 1 or 2, which method comprises maintaining a host cell as defined in claim 7 under conditions suitable for obtaining expression of the polypeptide and isolating the said s polypeptide.